The combination of YAP and RAF or MEK inhibition synergizes the cytotoxicity of RAF and MEK inhibitors to BRAF- and K-ras-mutant NSCLC cells [70]. The gene discussed is KRAS; the disease is non-small cell lung carcinoma.